Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use.[4] Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.[5][6]
The company had a previously fraught relationship with the United States Food and Drug Administration (FDA) due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval.[7][8] 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014,[9][10][11] and in the UK since December 2014.[12]
23andMe became a publicly traded company, via a merger with a Special Purpose Aquisition Company (SPAC) in 2021 and soon had a market capitalization of US$6 billion.[13] By 2024, its valuation had fallen to 2% of that peak.[13] On September 17, 2024, all seven independent directors of the company resigned, voicing concerns about the strategic direction of the company and Wojcicki's stated intention to take the company private.[14][15] Users were concerned about the security of their genetic data, and were trying to delete it from the company's archives.
History
Linda Avey, Paul Cusenza and Anne Wojcicki founded 23andMe in 2006 to offer genetic testing and interpretation to individuals.[2] Investment documents from 2007 also suggest that 23andMe hoped to develop a database to pursue research efforts.[16] In 2007, Google invested $3.9 million in the company, along with Genentech, New Enterprise Associates, and Mohr Davidow Ventures.[17] Wojcicki and Google co-founder Sergey Brin were married at the time.[10]
In 2007, Cusenza left to join Nodal Exchange as CEO.[18] Avey left in 2009 and co-founded Curious, Inc. in 2011.[19]
In 2012, 23andMe raised $50 million in a Series D venture round, almost doubling its capital of $52.6 million.[20] In 2015, 23andMe raised $115 million in a Series E offering, increasing capital to $241 million.[8]
In September 2017, it was rumored the company was raising another $200 million with a $1.5 billion valuation. As of that time, the company had raised $230 million since its inception.[23] Afterwards, it was reported the company raised $250 million, at a $1.75 billion valuation.[24]
On July 25, 2018, 23andMe announced a partnership with GlaxoSmithKline to allow the pharmaceutical company to use test results from 5 million customers to design new drugs. GlaxoSmithKline invested $300 million in the company.[25] In January 2022, this partnership was extended until July 2023 with an additional $50 million payment from GlaxoSmithKline.[26]
The company was based in Mountain View, California, initially in North Bayshore and then downtown,[27] until 2019, when it moved to a larger headquarters in Sunnyvale.[28][29] In January 2020, 23andMe announced it would lay off about 100 employees in its consumer testing division.[30][31]
In July 2020, 23andMe and GlaxoSmithKline announced their partnership's first clinical trial: a joint asset being co-developed by the two companies for cancer treatment.[32] In December 2020, the company raised around $82.5 million in a series F round, bringing the total raised over the years to over $850M. The post-money valuation was not reported.[33]
In February 2021, the company announced that it had entered into a definitive agreement to merge with Sir Richard Branson's special-purpose acquisition company, VG Acquisition Corp, in a $3.5 billion transaction.[34] In June 2021, the company completed the merger with VG Acquisition Corp. The combined company was renamed to 23andMe Holding Co. and began trading on the Nasdaq stock exchange on June 17, 2021, under the ticker symbol "ME".[35][36]
In October 2021, 23andMe announced that it would acquire Lemonaid Health, a telehealth company, for $400 million with the deal closing in November.[37][38]
After 23andMe became a publicly traded company in 2021, it reached a market capitalization of $6 billion.[13] By 2024, its valuation had fallen to 2% of that peak.[13] Suggested factors include the fact that the company has never been profitable, with lack of recurring revenue from 23andMe's retail customers of its DNA kits (who only need to take the test once).[39] In 2022, the company moved from Sunnyvale to a smaller headquarters in South San Francisco.[29][40] In June 2023, it announced another round of layoffs.[41]
In July 2024, Wojcicki announced her intention to take 23andMe private, by paying 40 cents each for all outstanding shares not already owned by her directly or through affiliates.[42] The proposal was rejected by a committee set up to evaluate options for the company's future,[43] and in September the seven independent members of the board of directors all resigned.[14][15][44][45] The company subsequently filed with the SEC indicating that it was no longer open to third-party acquisition offers.[42]
A 23andMe 2021 genome testing kitA 23andMe 2013 genome testing kit
23andMe began offering direct-to-consumer genetic testing in November 2007. Customers provide a saliva testing sample that is partially single nucleotide polymorphism (SNP) genotyped and results are posted online.[2][46][47] In 2008, when the company was offering estimates of "predisposition for more than 90 traits and conditions ranging from baldness to blindness", Time magazine named the product "Invention of the Year".[5]
After the sample is received by the lab, the DNA is extracted from the saliva and amplified so that there is enough to be genotyped. The DNA is then cut into small pieces, and applied to a glass microarray chip, which has many microscopic beads applied to its surface. Each bead has a gene probe on it that matches the DNA of one of the many variants the company test for. If the sample has a match in the microarray, the sequences will hybridize, or bind together, letting researchers know that this variant is present in the customer's genome by a fluorescent label located on the probes. Tens of thousands of variants are tested out of the 10 to 30 million located in the entire genome. These matches are then compiled into a report that is supplied to the customer, allowing them to know if the variants associated with certain diseases, such as Parkinson's, celiac and Alzheimer's, are present in their own genome.[48]
Uninterpreted raw genetic data may be downloaded by customers.[49] This provides customers with the ability to choose one of the 23 chromosomes, as well as mitochondrial DNA, and see which base is located in certain positions in genes, and see how these compare to other common variants. Customers who bought tests with an ancestry-related component have online access to genealogical DNA test results and tools, including a relative-matching database. Customers can also view their mitochondrial haplogroup (maternal) and, if they are male or a relative shared a patriline that has also been tested, Y chromosome haplogroup (paternal). US customers who bought tests with a health-related component and received health-related results before November 22, 2013, have online access to an assessment of inheritedtraits and genetic disorder risks.[7][50][51] Health-related results for US customers who purchased the test from November 22, 2013, were suspended until late 2015 while undergoing an FDA regulatory review.[8][52] Customers who bought tests from 23andMe's Canadian and UK locations have access to some, but not all, health-related results.[9][12]
As of February 2018, 23andMe has genotyped over 3,000,000 individuals.[53] FDA marketing restrictions reduced customer growth rates.[54] In February 2024, 23andMe said they had genotyped more than 14,000,000 individuals.[55]
In late 2009, 23andMe split its genotyping service into three products with different prices: an Ancestry Edition, a Health edition, and a Complete Edition.[57] This decision was reversed a year later, when the different products were recombined.[58] In late 2010, the company introduced a monthly subscription fee for updates based on new medical research findings.[58][59] The subscription model proved unpopular with customers and was eliminated in mid-2012.[60]
23andMe only sold raw genetic data and ancestry-related results in the US due to FDA restrictions from November 22, 2013, until October 21, 2015,[7][52] when it announced that it would resume providing health information in the form of carrier status and wellness reports with FDA approval.[61]
The price of the full direct-to-consumer testing service in the US reduced from $999 in 2007 to $399 in 2008[62] and to $99 in 2012,[20] and was effectively being sold as a loss leader in order to build a valuable customer database.[49][63][64] In October 2015, the US price was raised to $199.[61] In September 2016, an ancestry-only version was once again offered at a lower price of $99 with an option to upgrade to include the health component for an additional $125 later.[65]
The initial price of the product sold in Canada from October 2014, which includes health-related results, was CA$99.[9][10] The initial price of the product sold in the UK from December 2014, which includes health-related results, was £125.[66]
In February 2018, 23andMe announced that its ancestry reporting would tell people what country they were from, not just what region, and increased the number of regions by 120. Like other companies, it still lacked data about Asia and Africa, which the African Genetics Program (launched in October 2016 with a grant from the US National Institutes of Health) will rectify by recruiting sub-Saharan Africans to increase the genomic data on racial and ethnic minorities.[67][68] Building off of the African Genetics Program, the Global Genetics Program was also announced in February 2018. This program aims to increase the genomic data of 61 underrepresented countries in their database by providing free tests to individuals that have all 4 grandparents from one of the countries. In April 2018, 23andMe announced the Populations Collaboration Program, which sets up formal collaborations between the company and researchers that are investigating underrepresented countries.[69]
Additional services
Since October 1, 2020, the company has offered a new service called "23andMe+", priced at $29/year, for the customers of the "Health + Ancestry" service, who completed genotyping on version 5 of the microarray chip used by the company. The new service makes available additional reports on health and pharmacogenetics, and commits to provide ongoing new reports and features.[70]
Lemonaid Health acquisition
At the end of 2021, 23andMe acquired leading digital healthcare company Lemonaid Health for $400m to "...give patients and healthcare providers better information about health risks and treatment". Paul Johnson, CEO and co-founder of Lemonaid Health became COO of the 23andMe consumer business.[71][72][73]
Instrument and chip versions
Up until 2010, Illumina only sold instruments that were labeled "for research use only"; in early 2010, Illumina obtained FDA approval for its BeadXpress system to be used in clinical tests.[74][75]
Government regulation in the United States
The new genetic testing service and ability to map significant portions of the genome has raised controversial questions, including whether the results can be interpreted meaningfully and whether they will lead to genetic discrimination.[5][49] The regulatory environment for genetic testing companies has been uncertain, and anticipated risk-based regulation for different types of genetic tests has not yet materialized.[58][76][77]
State regulators
In 2008, New York and California each provided notice to 23andMe and similar companies that those companies needed to obtain a CLIA license in order to sell tests in those states.[5][78][79] By August 2008, 23andMe had received licenses that allow them to continue to do business in California.[80]
FDA
According to Anne Wojcicki, 23andMe has been in dialogue with the FDA since 2008.[77] In 2010, the FDA notified several genetic testing companies, including 23andMe, that their genetic tests are considered medical devices and federal approval is required to market them; a similar letter was sent to Illumina, which makes the instruments and chips used by 23andMe in providing its service.[58][81][82] 23andMe first submitted applications for FDA clearance in July and September 2012.[83]
In November 2013, the FDA published guidance on how it classified genetic analysis and testing services offered by companies using instruments and chips labelled for "research use only" and instruments and chips that had been approved for clinical use.[84]
At around the same time, after not hearing from 23andMe for six months, the FDA ordered 23andMe to stop marketing its saliva collection kit and personal genome service (PGS), as 23andMe had not demonstrated that they have "analytically or clinically validated the PGS for its intended uses" and that the "FDA is concerned about the public health consequences of inaccurate results from the PGS device".[83][85][86] As of December 2, 2013[update], 23andMe had stopped all advertisements for its PGS test but is still selling the product.[87][88] As of December 5, 2013[update], 23andMe was selling only raw genetic data and ancestry-related results.[7][52]
23andMe publicly responded to media reports on November 25, 2013, stating, "We recognize that we have not met the FDA's expectations regarding timeline and communication regarding our submission. Our relationship with the FDA is extremely important to us and we are committed to fully engaging with them to address their concerns."[89][90][91] CEO Anne Wojcicki subsequently posted an update on the 23andMe website, stating: "This is new territory for both 23andMe and the FDA. This makes the regulatory process with the FDA important because the work we are doing with the agency will help lay the groundwork for what other companies in this new industry do in the future. It will also provide important reassurance to the public that the process and science behind the service meet the rigorous standards required by those entrusted with the public's safety."[77]
On December 5, 2013, 23andMe announced that it had suspended health-related genetic tests for customers who purchased the test from November 22, 2013, in order to comply with the FDA warning letter, while undergoing regulatory review.[7][52]
In May 2014, it was reported that 23andMe was exploring alternative locations abroad, including Canada, Australia, and the United Kingdom, in which to offer its full genetic testing service.[92] 23andMe had been selling a product with both ancestry and health-related components in Canada since October 2014,[9][10][11] and in the UK since December 2014.[12]
In 2014, 23andMe submitted a 510(k) application to the FDA to market a carrier test for Bloom syndrome, which included data showing that 23andme's results were consistent and reliable and that the saliva collection kit and instructions were easy enough for people to use without making mistakes that might affect their results, and included citations to the scientific literature showing that the specific tests that 23andMe offered were associated with Blooms.[93][94] The FDA cleared the test in February 2015; in the clearance notice, the FDA said that it would not require similar applications for other carrier tests from 23andMe.[93][95] The FDA sent further clarification about regulation of the test to 23andMe on October 1, 2015.[96]
On October 21, 2015, 23andMe announced that it would begin marketing carrier tests in the US again.[8] Wojcicki said, "There was part of us that didn’t understand how the regulatory environment works" in regards to the distributed laboratory regulatory functions of FDA and Centers for Medicare and Medicaid Service (CMS).[97]
In March 2018, the FDA approved another de novo application from the company, this one for a direct-to-consumer test for three specific BRCA mutations that are the most common BRCA mutations in people of Ashkenazi descent; they are not however the most common BRCA mutations in the general population, and the test is only for three of the approximately 1,000 known mutations.[100] These mutations increase the risk of breast and ovarian cancer in women, and the risk of breast and prostate cancer in men.[101]
COVID-19
This section needs to be updated. Please help update this article to reflect recent events or newly available information.(January 2024)
In June 2020, 23andMe published results from a study that claimed that people with type O blood may be at lower risk of catching COVID-19. Out of more than 750,000 participants, those with type O blood were 9–18% less likely to contract the virus, while those who had been exposed were 13–26% less likely to test positive.[102][103][104] The study was published in April 2021.[105]
Informed consent and privacy concerns
Questions have been raised since at least 2013 as to whether the company can obtain informed consent through its web-based interactions with people who want to submit samples for sequencing.[106][107]
The company collects not only genetic and personal information from customers who order DNA tests, but also data about other web behavior information that 23andMe captures through the use of its website, products, software, cookies, and through its smartphone app.[108][109] A combination of several individual policies within the terms of service and privacy policy (cookies, disclosure of aggregate data, targeted advertising) makes 23andMe a valuable data mine for third parties such as health insurance companies, pharmaceutical companies, advertising companies, biotechnology companies, law enforcement, or other interested parties.[110][111][112] People may not actually be aware of how the company uses the data, and there are always risks of data breaches.[113][114] Personal information of customers of 23andMe “may be accessed, sold or transferred”.[115]
United States
Depending on which state an individual resides in, 23andMe must follow that state's laws regarding privacy and disclosing information. Since 23andMe is not a medical provider, the company does not have to abide by standard privacy policies that must be followed at a doctor's office, such as the Health Insurance Portability and Accountability Act (HIPAA).[114] Research by Deloitte has shown that only 9% of consumers actually read the terms and conditions, and research from ProPrivacy concluded that only 1% of consumers read the policies, which suggests that consent to be included in research may have been given without full knowledge of the permissions being given.[116] In addition, 23andMe's privacy policy can be confusing for consumers to understand.[117] Despite confusion, 23andMe’s informed consent practices are approved by an institutional review board. Several sections of the privacy policy allows data to be disclosed to third parties, regardless whether the consent is signed:
Section 4(b) "We permit third party advertising networks and providers to collect Web-Behavior Information regarding the use of our Services to help us to deliver targeted online advertisements ('ads') to you."[108]
Section 4(c): "Regardless of your consent status, we may also include your data in aggregate data that we disclose to third-party research partners who will not publish that information in a scientific journal."[118]
Section 4(d): "We may share some or all of your Personal Information with other companies under common ownership or control of 23andMe, which may include our subsidiaries, our corporate parent, or any other subsidiaries owned by our corporate parent in order to provide you better service and improve user experience."[108]
The Genetic Information Nondiscrimination Act (GINA) protects a person against discrimination based on genetic information by their employer(s) or insurance companies in most situations. However, GINA does not extend to discrimination based on genetic information for long-term care or disability-insurance providers.
European Union
Effective 25 May 2018, 23andMe must abide by the General Data Protection Regulation (GDPR).[119][120] The GDPR is a set of rules/regulations that helps an individual take control of their data information that is collected, used and stored digitally or in a structured filing system on paper, and restricts a company's use of personal data.[120] The regulation also applies to companies who offer the company's products/services outside of the EU.[120]
Medical research
Over 80% of 23andMe customers have opted in to having their data used in research.[121][122]
Aggregated customer data is studied by scientific researchers employed by 23andMe for research on inherited disorders; rights to use customers' data is also sold to pharmaceutical and biotechnology companies for use in their research.[8][49][123] The company also collaborates with academic and government scientists.[124][54] In July 2012, 23andMe acquired the startup CureTogether, a crowdsourced treatment ratings website with data on over 600 medical conditions.[125] 23andMe has an optional consent that enables the individual's genetic information to be included in medical research that may be published in a scientific journal. However, if an individual chooses not to consent for their 'personal information' to be used, their 'genetic information' and 'self-reported information' may still be used and shared with the company's third party service providers.[108][112]
In 2010, 23andMe said that it was able to use its database to validate work published by the NIH: identifying mutations in the gene that codes for glucocerebrosidase as a risk factor for Parkinson's disease.[124]
In 2015, 23andMe made a business decision to pursue drug discovery themselves, under the direction of former Genentech executive Richard Scheller.[8][126] One of their main focuses is Parkinson's disease, and they are utilizing the 23andMe database to search for rare variants associated with Parkinson's in the hope of developing a drug for the disease. The company also set up research agreements with the pharmaceutical company Pfizer to explore the genetic causes of inflammatory bowel disease, namely ulcerative colitis and Crohn's disease.[127][128]
In 2016, a project that the company was developing to provide customers with next generation sequencing was ended, because of the fear that the results would be too complicated or vague to fit into the company's goal of providing useful information, both quickly and precisely, directly to consumers, according to Wojcicki.[129] Also in 2016, 23andMe used self-reported data from customers to locate 17 genetic loci that seem to be associated with depression.[130]
In 2017, 23andMe, the Lundbeck pharmaceutical company, and the Milken Institute think tank started collaborations to focus on psychiatric disorders, such as bipolar disorder and major depression. Their goals are to determine the genetic roots of such disorders, as well as pursue drug discovery in those areas.[131]
Use by law enforcement
23andMe's transparency report states that they had received requests from law enforcement for 15 US users' data since 2015 as of September 2024, and none from other countries. Data Produced (By User Account) was zero.[132] The 23andMe Privacy Policy states that customers "can rest assured, we will not voluntarily share your Personal Information with... Law enforcement, absent a valid court order, subpoena, or search warrant".[133]
In October 2023, a significant data breach occurred and sensitive information of 23AndMe users was stolen. Hackers stole 7 million people's data, about half of 23andMe's customers at the time. Stolen information included people's names, addresses and genetic data and was sold online.[134][135]
The company claimed that it was a credential stuffing incident rather than a breach into their systems. The hackers targeted Ashkenazi Jews and users of Chinese descent and are attempting to sell the stolen information. The affected accounts had enabled the platform's "DNA Relatives" feature, which helps users find genetic relatives and connect with each other.[136][137]
Financial problems
At the end of 2024 23AndMe was in serious financial trouble, losing 98% of its US$6bn value. Many of its 15 million customers, concerned about security of their DNA data stored by the company given its uncertain future, were attempting to delete it.[138]
^Greely, Hank (November 25, 2013). "The FDA drops an anvil on 23andMe – now what?". Stanford University. Archived from the original on November 29, 2013. Retrieved November 29, 2013. FDA had promised a risk-based regulatory scheme, but we don't know what it is.
Ini adalah nama Korea; marganya adalah Jung. Jung Suk-wonLahir16 Mei 1985 (umur 38)Incheon, Korea SelatanPendidikanIncheon City College - Martial ArtsPekerjaanAktorTahun aktif2008-sekarangAgenC-JeS EntertainmentSuami/istriBaek Ji-young (m. 2013) Nama KoreaHangul정석원 Alih AksaraJeong Seok-wonMcCune–ReischauerChŏng Sŏk-wŏn Jung Suk-won (Hangul: 정석원; lahir 16 Mei 1985) adalah aktor asal Korea Selatan.[1][2][3] Ia memulai kariernya di dun...
Fierozzo commune di Italia Fierozzo (it) Tempat categoria:Articles mancats de coordenades Negara berdaulatItaliaRegion otonom dengan status khususTrentino-Tirol SelatanProvinsi di ItaliaTrentino NegaraItalia Ibu kotaSan Felice PendudukTotal470 (2023 )GeografiLuas wilayah17,94 km² [convert: unit tak dikenal]Ketinggian1.127 m Berbatasan denganFrassilongo Palù del Fersina Roncegno Terme Sant'Orsola Terme Torcegno SejarahSanto pelindungLaurensius Informasi tambahanKode pos38050 Zona ...
VII Asian GamesTuan rumahTeheran IranJumlah negara25Jumlah atlet3010Jumlah disiplin16 Cabang OlahragaUpacara pembukaan1 SeptemberUpacara penutupan16 SeptemberDibuka olehMohammad Reza PahlaviShah IranJanji atletMansour BarzegarPenyalaan oborGolverdi PeymaniTempat utamaAryamehr Stadium← Bangkok 1970 Bangkok 1978 → Asian Games 1974 adalah Asian Games yang ke-7 dan diselenggarakan di Teheran, Iran dari 1 September 1974 sampai 16 September 1974. 3010 atlet berlaga, datang dari 25 ...
2008 studio album by Dino MerlinIspočetkaStudio album by Dino MerlinReleased9 June 2008 (2008-06-09)Recorded2004–2008GenrePop rockFolk popLabelMPBHRTCroatia RecordsCity RecordsShopNovellaProducerDino Merlin (executive)Dino Merlin chronology Burek(2004) Ispočetka(2008) Hotel Nacional(2014) Singles from Ispočetka Otkrit ću ti tajnuReleased: 13 August 2007 Dabogda (feat. Hari Mata Hari)Released: May 2008 Da šutiš (Indigo) (feat. Eldin Huseinbegović)Released: July...
The Tale of NokduPoster promosiHangul조선로코-녹두전 GenreSejarahKomedi romantis[1]BerdasarkanJoseon Rom-com Tale of Nok-duoleh Hye Jin-yangDitulis olehBaek So-yeonLim Ye-jinSutradaraKim Dong-hwiPemeranJang Dong-yoonKim So-hyunKang Tae-ohJung Joon-hoLagu pembukaMiracle by Woozi (Seventeen)Lagu penutupI'll Be The Light oleh YounhaNegara asalKorea SelatanBahasa asliKoreaJmlh. episode32ProduksiPengaturan kameraSingle-cameraDurasi35 menitRumah produksiProduction HMonster Union[...
2008 film by Jennifer Lynch SurveillanceDirected byJennifer LynchWritten byKent Harper Jennifer LynchProduced byMarco Mehlitz Gary Hamilton Harrison KordestaniStarring Bill Pullman Julia Ormond Pell James Michael Ironside French Stewart CinematographyPeter WunstorfEdited byDaryl K. DavisMusic byTodd BryantonDistributed byArclight Films, Wild Bunch DistributionRelease date May 21, 2008 (2008-05-21) (Cannes Film Festival) Running time97 minutes[1]CountryUnited StatesL...
فيليب-فرانسوا-جوزيف لي باس معلومات شخصية اسم الولادة (بالفرنسية: Philippe François Joseph Le Bas) الميلاد 4 نوفمبر 1762 فريفينت الوفاة 28 يوليو 1794 (31 سنة) باريس سبب الوفاة إصابة بعيار ناري مكان الدفن باريس مواطنة فرنسا الأولاد فيليب لي باس مناصب [1] ...
Place in Västergötland, Sweden For the fossil crustacean, see Skara (crustacean). This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Skara – news · newspapers · books · scholar · JSTOR (October 2010) (Learn how and when to remove this template message) Place in Västergötland, SwedenSkaraSkara Cathedral Coat...
У этого термина существуют и другие значения, см. Купидон (значения). Купидон Мифология римская Пол мужской Отец Марс Мать Венера Атрибуты лук и стрелы В иных культурах Кама, Эрот Медиафайлы на Викискладе Купидон (лат. Cupīdō [kʊˈpiːdoː]; «страстное желание») — в рим�...
For other people named Ariarathes, see Ariarathes (disambiguation). 4th-century BC king of Cappadocia AriarathesCoin of Ariarathes I, minted in Gaziura, dated 333–322 BCSatrap of Northern CappadociaIn office340s BC – 331 BCPreceded byAriamnes ISucceeded byHimself (as King of Cappadocia)King of CappadociaIn office331 BC – 322 BCPreceded byHimself (as Satrap of Northern Cappadocia)Succeeded byVacant (title next held by Ariarathes II Personal detailsBorn405/4 BCDied322 BC...
Pour les articles homonymes, voir Bertrand et Léon Bertrand. Léon Bertrand Fonctions Ministre délégué au Tourisme (secrétaire d'État jusqu'au 30 mars 2004) 17 juin 2002 – 15 mai 2007(4 ans, 10 mois et 28 jours) Président Jacques Chirac Gouvernement Raffarin II et IIIVillepin Prédécesseur Gilles de Robien (ministre) Successeur Luc Chatel (secrétaire d'État) Député français 23 juin 1988 – 19 juillet 2002(14 ans et 26 jours) Élection 12 juin 1988 Ré...
La Grotte de Platon, attribué à Michiel Coxcie, milieu du XVIe siècle. Huile sur bois de peuplier. Musée de la Chartreuse, Douai. L’allégorie de la caverne est une allégorie exposée par Platon dans La République. Elle expose en termes imagés les conditions d'accession de l'humain à la connaissance du Bien, au sens métaphysique du terme, ainsi que la transmission de cette connaissance. L'allégorie met en scène des humains enchaînés et immobilisés dans une caverne. Ils to...
Peta La Lantejuela dalam Peta Topografi Nasional Spanyol. Skala yang digunakan pada peta adalah 1:25.000 (1 sentimeter = 250 meter). La Lantejuela merupakan sebuah kota yang terletak di wilayah Provinsi Sevilla, Andalusia, Spanyol Lihat juga Daftar munisipalitas di Seville Daftar munisipalitas di Spanyol lbsKota di Provinsi Sevilla Aguadulce Alanís Albaida del Aljarafe Alcalá de Guadaíra Alcalá del Río Alcolea del Río Algámitas Almadén de la Plata Almensilla Arahal Aznalcázar Aznalc�...
Former theatre in Manhattan, New York General informationLocationManhattan, New YorkOpened1928Closed1970Demolished1970 The Adelphi Theatre (1934–1940 and 1944–1958), originally named the Craig Theatre, opened on December 24, 1928. The Adelphi was located at 152 West 54th Street in Manhattan, with 1,434 seats.[1] The theater was taken over by the Federal Theater Project in 1934 and renamed the Adelphi. The theater was renamed the Radiant Center by The Royal Fraternity of Master Me...
Questa voce o sezione sull'argomento gruppi musicali è ritenuta da controllare. Motivo: molti link a Discogs e imdb Partecipa alla discussione e/o correggi la voce. Segui i suggerimenti del progetto di riferimento. La Bionda Paese d'origine Italia GenereDiscoDanceMusica acustica (primi due album)Pop Periodo di attività musicale1970 – in attività EtichettaBaby Records Emergency Records La Bionda Music Album pubblicati9 Studio9 Modifica dati su Wikidata...
Historic district in New York, United States United States historic placeCity Hall Historic DistrictU.S. National Register of Historic PlacesU.S. Historic district The old Rochester City Hall in June 2010Show map of New YorkShow map of the United StatesLocationS. Fitzhugh St. between Broad and W. Main Sts., Rochester, New YorkyCoordinates43°9′16″N 77°36′50″W / 43.15444°N 77.61389°W / 43.15444; -77.61389Area3 acres (1.2 ha)Built1848ArchitectWarner, A.J....
2004 treaty on refugee management Canada–United States Safe Third Country AgreementAgreement between the Government of Canada and the Government of the United States of America for cooperation in the examination of refugee status claims from nationals of third countriesTypeBilateral treatySignedDecember 5, 2002 (2002-12-05)LocationWashington, D.C.EffectiveDecember 29, 2004Originalsignatories Bertin Côté Arthur E. Dewey Parties Canada United States CitationsCTS 2...
2023 English local election 2023 Tonbridge and Malling Borough Council election ← 2019 4 May 2023 (2023-05-04) 2027 → All 44 seats to Tonbridge and Malling Borough Council23 seats needed for a majorityTurnout35.8% First party Second party Third party Leader Matt Boughton[1] Anita Oakley April Clark Party Conservative Liberal Democrats Green Last election 39 seats, 46.9% 9 seats, 19.5% 2 seats, 11.5% Seats won 20 11 8 Seat...
